Steps Against the Burden of Parkinson's Disease - RCT Kiel
StepuP
1 other identifier
interventional
42
1 country
1
Brief Summary
Parkinson's disease (PD) affects over 10 million worldwide, causing unstable gait and falls in 70% of patients despite medication. This leads to confidence loss, isolation, fractures, and hospitalizations. Treadmill training, augmented by mechanical/virtual-reality triggers, has proven effective in enhancing gait and reducing falls. However, underlying treadmill training mechanisms are unclear. To personalize training, we'll explore how PD patients benefit and transfer effects to daily life. This trial is part of three parallel randomized controlled trials within the Steps Against the Burden of Parkinson's Disease (CT-IDs: 6ef2e427b002, 6ef2e427b003, 6ef2e427b004) project, which will perform a pooled analysis across all sites in addition to individual RCT analyses. Each trial adheres to a shared core protocol while allowing for adaptations in the perturbation protocol, ensuring that data can be combined. Importantly, mechanistic findings and outcomes from this specific RCT will be reported independently, but also as part of a pooled analysis. In this trials, PD patients will undergo treadmill training with and without adaptations (perturbations). 12 sessions of treadmill training will be provided, with pre/post assessments and a Follow-up 12±2 weeks following T1 with pre/post assessments and a Follow-up 12±2 weeks following T1 at 8 to 12 weeks after the post assessment. For post treadmill training a phone app will be offered as a home-based speed dependent walk training intervention. This intervention is an App based training for gait adaptability and allows users to set their own training time and pace. It delivers a rhythmic metronomic beat for three different walking speeds, designed to trigger movement and encourage better walking patterns. Gait improvements are expected, driven by sensorimotor integration improving balance control. Biomechanical data analysis will reveal enhanced foot placement control. Neurophysiological changes will be studied through EEG and EMG, aiming to find improved gait stability with reduced EEG beta power and increased EEG-EMG coherence. Gait improvement in the lab might not correlate with daily-life results. Gait self-efficacy could influence transfer, prompting investigation into mechanistic associations with mobility outcomes. Remote digital tools will assess week-long mobility outcomes, employing machine learning to comprehend why some improve both in lab and life, while others don't. This will uncover mechanisms translating treatment effects into real-world outcomes, aiding personalized intervention development.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable parkinson-disease
Started Jul 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 25, 2024
CompletedFirst Submitted
Initial submission to the registry
March 26, 2025
CompletedFirst Posted
Study publicly available on registry
July 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2026
CompletedJuly 10, 2025
June 1, 2025
1.7 years
March 26, 2025
June 30, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Gait speed - T0
Comfortable walking speed overground
Baseline
Gait speed - T1
Comfortable walking speed overground
After Intervention (2-12 weeks)
Gait speed - T2
Comfortable walking speed overground
After Follow-up 12±2 weeks following T1 (20-32 weeks)
Secondary Outcomes (77)
Fall events (occurrence and frequency) and fall related injuries - T0
Baseline (T0)
Fracture history - T0
Baseline (T0)
Medication - T0
Baseline (T0)
Medication - T1
After Intervention (2-12 weeks)
Medication - T2
Follow-up 12±2 weeks following T1
- +72 more secondary outcomes
Study Arms (2)
Kiel
EXPERIMENTALIn Kiel, the experimental group will engage in 12-sessions of SDTT with additional anteroposterior perturbations, contrasting with the control group undergoing regular SDTT.
Control
ACTIVE COMPARATORInterventions
This training methodology focuses on adjusting the treadmill's speed according to the individual's walking pace, creating a more dynamic and adaptive exercise environment. SDTT is designed to mimic real-world walking conditions and challenges, promoting neuromuscular coordination, balance, and overall mobility. By tailoring the treadmill speed to match the user's gait, SDTT encourages the development of natural and efficient walking patterns. This training technique has shown promise in various clinical settings, aiding individuals with gait impairments caused by neurological conditions, musculoskeletal disorders, or post-injury rehabilitation. Its adaptability allows for progressive adjustments as a person's walking abilities improve, making it a versatile tool for optimizing gait mechanics and functional mobility. o ensure continued progress and integration into daily life, home-based walking training, supported by a phone application, will be included between T1 and T2.
The SDTT+ anteroposterior perturbations program will trigger reactive gait adaptations by accelerations and decelerations of one of the belts of a split-belt treadmill.
Eligibility Criteria
You may qualify if:
- Diagnosis of PD according to the MDS Criteria
- Hoehn and Yahr stages I to III;
- Movement Disorder Society-sponsored version of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) gait sub-score of 1 or more
- Signed informed consent to participation
You may not qualify if:
- Any known general health condition likely to interfere with or to pose a contraindication to non-medically supervised physical exercise.
- Moderate or severe depression (BDI-II ≥18)
- Cognitive impairment which may preclude the possibility to provide a fully informed consent to enrolment.
- Linguistic comprehension capacity less than 75% in ordinary conversation
- Severe psychiatric comorbidity which may interfere with compliance to the study protocol
- History of or current status of substance dependency
- Unable to walk less than 1 floor
- Thoracic pain in the last 4 weeks
- Currently enrolled in other interventional studies
- Implanted Deep Brain Stimulation device
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Kiel
Kiel, 24105, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr.
Study Record Dates
First Submitted
March 26, 2025
First Posted
July 10, 2025
Study Start
July 25, 2024
Primary Completion
March 30, 2026
Study Completion
April 30, 2026
Last Updated
July 10, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ANALYTIC CODE
To ensure high standards of data curation, the widely accepted Brain Imaging Data Structure (BIDS) standard to store the motion, EMG and EEG data will be followed and data will be made public in a coded, de-identified manner.